 | Up a level |
Wirsching, H-G; Tabatabai, G; Roelcke, U; Hottinger, A F; Jörger, F; Schmid, A; Plasswilm, Ludwig; Schrimpf, D; Mancao, C; Capper, D; Conen, K; Hundsberger, T; Caparrotti, F; von Moos, R; Riklin, C; Felsberg, J; Roth, P; Jones, D T W; Pfister, S; Rushing, E J; ... (2018). Bevacizumab plus hypofractionated radiotherapy versus radiotherapy alone in elderly patients with glioblastoma: the randomized, open-label, phase II ARTE trial. Annals of oncology, 29(6), pp. 1423-1430. Oxford University Press 10.1093/annonc/mdy120
